[go: up one dir, main page]

CL2018002602A1 - Composición y método para el tratamiento del deterioro cognitivo. - Google Patents

Composición y método para el tratamiento del deterioro cognitivo.

Info

Publication number
CL2018002602A1
CL2018002602A1 CL2018002602A CL2018002602A CL2018002602A1 CL 2018002602 A1 CL2018002602 A1 CL 2018002602A1 CL 2018002602 A CL2018002602 A CL 2018002602A CL 2018002602 A CL2018002602 A CL 2018002602A CL 2018002602 A1 CL2018002602 A1 CL 2018002602A1
Authority
CL
Chile
Prior art keywords
percent
composition
weight
treatment
cognitive impairment
Prior art date
Application number
CL2018002602A
Other languages
English (en)
Inventor
Eddy C Betancour-Villamizar
Juan Murcillo-Rojas
Ruben Betancourt-Cortes
Original Assignee
Team Foods Colombia Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Team Foods Colombia Sa filed Critical Team Foods Colombia Sa
Publication of CL2018002602A1 publication Critical patent/CL2018002602A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN, EN LAS REALIZACIONES, ES UNA COMPOSICIÓN Y MÉTODO DE TRATAMIENTO QUE USA UNA COMPOSICIÓN QUE INCLUYE: UN PRIMER COMPONENTE QUE COMPRENDE: 75 A 97 POR CIENTO EN PESO DE TRIGLICÉRIDOS DE CADENA MEDIA; EN DONDE LOS TRIGLICÉRIDOS DE CADENA MEDIA COMPRENDEN ÉSTERES DE ÁCIDO GRASO DE GLICEROL DE 6 A 12 ÁTOMOS DE CARBONO; 4 A 15 POR CIENTO EN PESO DE LECITINA DE SOYA; 0,05 A 1 POR CIENTO EN PESO DE BIOTINA Y 0,01 A 0,2 POR CIENTO EN PESO DE ANTIOXIDANTE, Y ACEITE DE OLIVA, EN DONDE EL ANTIOXIDANTE SE SELECCIONA DEL GRUPO QUE CONSISTE EN TOCOFEROL, PALMITATO DE ASCORBILO, EXTRACTO DE ROMERO Y MEZCLAS DE LOS MISMOS.
CL2018002602A 2016-03-14 2018-09-11 Composición y método para el tratamiento del deterioro cognitivo. CL2018002602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662307714P 2016-03-14 2016-03-14

Publications (1)

Publication Number Publication Date
CL2018002602A1 true CL2018002602A1 (es) 2018-11-30

Family

ID=58993159

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002602A CL2018002602A1 (es) 2016-03-14 2018-09-11 Composición y método para el tratamiento del deterioro cognitivo.

Country Status (7)

Country Link
US (1) US10869852B2 (es)
EP (1) EP3429578B1 (es)
CL (1) CL2018002602A1 (es)
CO (1) CO2018009407A2 (es)
ES (1) ES2925058T3 (es)
MX (1) MX387772B (es)
WO (1) WO2017158427A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009763A (es) * 2000-04-04 2003-03-27 Shionogi & Co Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa.
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
GB0115982D0 (en) * 2001-06-29 2001-08-22 Oaklea Ltd Stabilisation of chlorophyll
WO2003104433A2 (en) * 2002-06-11 2003-12-18 Pasteuria Bioscience Llc Materials and methods for in vitro production of bacteria
US20130017278A1 (en) * 2011-07-13 2013-01-17 Arlene Keller Composition and method for improving brain function

Also Published As

Publication number Publication date
EP3429578B1 (en) 2022-08-10
WO2017158427A1 (en) 2017-09-21
CO2018009407A2 (es) 2018-10-22
US20190076387A1 (en) 2019-03-14
ES2925058T3 (es) 2022-10-13
MX2018011058A (es) 2019-06-20
US10869852B2 (en) 2020-12-22
MX387772B (es) 2025-03-18
EP3429578A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
CL2018001361A1 (es) Inhibidores éster de acc y usos de los mismos
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
CL2017001124A1 (es) Agentes inmunomoduladores
CO2019000672A2 (es) Procedimiento de tratamiento de dismenorrea y dolor menstrual
BR112016025504A2 (pt) composições para cuidado de lavanderia
AR098893A1 (es) Proceso para obtener aceite microbiano a partir de células microbianas
MX2015009622A (es) Composiciones de cera y el efecto de metales en velocidades de combustion.
MX388428B (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de animo
BR112015020832A2 (pt) composição de sulfonato de olefina interna, e, método para tratamento de uma formação contendo petróleo bruto
CO2019005156A2 (es) Composición para el tratamiento y/o prevención de la enfermedad fúngica sigatoka negra en los cultivos de banana
CL2021001474A1 (es) Una composición que contiene un ácido graso altamente insaturado o un éster alquílico del mismo y un método para la producción del mismo
AR091872A1 (es) Intraesterificacion aleatoria
MX2018004128A (es) Composiciones de aceite y metodos para elaborarlas.
MX2019012745A (es) Estabilidad de aceites tratados con evaporación de recorrido corto.
MX386759B (es) Metodos para desengomar aceites.
CL2019001338A1 (es) Preparación cosmética de viscosidad mejorada para el tratamiento de las fibras queratínicas, proceso para el aumento de la viscosidad de una preparación cosmética, uso de ingredientes modificadores de la viscosidad y método de tratamiento de las fibras queratínicas.
BR112014017048A2 (pt) emulsão orgânica compreendendo dha e epa
CL2018002602A1 (es) Composición y método para el tratamiento del deterioro cognitivo.
EA201691628A1 (ru) Состав для личной гигиены
AR094913A1 (es) Transporte de petróleo pesado
MX2018008069A (es) Composicion lipida vegetal para promover el crecimiento del cabello, metodo para promover el crecimiento del cabello y uso de los lipidos vegetales.
BR112017005759A2 (pt) composição de preparação externa que contém s-flurbiprofeno
CL2017002828A1 (es) Composición para tratamiento de estrés oxidativo y enfermedad cardiovascular
BR112016029165A2 (pt) método para degomagem de composições contendo triglicerídeos
MX2018000708A (es) Composiciones y metodos para desgomar aceite.